Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia

BMC Public Health

Table 1 Population, vaccine, average influenza-related outcome rates and economic inputs (in A$) by subgroup of population

Population subgroup	Population			Vaccine coverage rate [29, 30]	Vaccine effectiveness [31]			Average Influenza Attack rate [23–25]	GP consultations		Hospitalisations		Mortality rate^c [32, 33]	Productivity loss per GP consultation
Population subgroup	Population size [22]	Proportion with RF [19–21]	Population at risk	Vaccine coverage rate [29, 30]	Against influenza A	Against matched B lineage	TIV B lineage cross-protection, % matched B effectiveness	Average Influenza Attack rate [23–25]	Rate^b [32]	Unit cost [34]	Rate^c [3]	Unit cost [35–37]	Mortality rate^c [32, 33]	Working days lost [38–40]	Income loss [41]
Children with RF (6–59 months)	1,331,660	13.0 %	173,778^a	41.3 %	59 %	66 %	67 %	18.8 %	91.0 %	$37	106	$3,944	0.6	0.64	$192
Children with RF (5–17 years)	3,673,678	13.9 %	509,239^a	41.3 %	61 %	75 %	67 %	16.5 %	63.6 %	$37	16	$4,811	0.1	0.64	$192
Adults with RF (18–49 years	10,220,627	21.8 %	2,223,249^a	36.2 %	61 %	77 %	68 %	3.6 %	62.6 %	$37	31	$5,644	0.3	2.59	$784
Adults with RF (50–64 years)	4,114,452	31.5 %	1,296,098^a	36.2 %	61 %	73 %	67 %	3.6 %	62.6 %	$37	91	$7,497	4.1	2.59	$784
Elderly (65 years and older)	3,221,321	-	3,221,312	74.6 %	58 %	69 %	68 %	4.9 %	72.2 %	$37	440	$10,141	91.3	0^d	$0^d

RF risk factor, TIV trivalent influenza vaccine, GP general practitioner, ^aOnly people with risk factor; ^bper influenza case; ^cper 100,000 population; ^dElderly were assumed to be economically inactive

ISSN: 1471-2458